Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Pain in Complex Regional Pain Syndrome
2022-503167-15-00Phase 2Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in complex regional pain syndrome (CRPS) comparing Ajovy with Placebo (2 arms). Primary endpoint: Change in average daily pain intensity. Planned start Jun 2023; status: authorised.
02
Drugs
fremanezumab
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on 2022-503167-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503167-15-00.